Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC

Prospective Antidementia Drug Improves Brain Function

By BiotechDaily International staff writers
Posted on 15 Oct 2012
A new antidementia drug candidate has been found to be highly active in creating new neuronal connections and improving the cognitive function of rats with Alzheimer’s-like mental impairment.

Researchers at Washington State University (WSU; Pullman, WA, USA) have developed a new compound, named Dihexa, designed to repair damage that has already occurred and thereby recover lost brain function. This is a significant departure from current treatments for diseases such as Alzheimer’s, treatments that only slow the process of cell death or inhibit the neurotransmitter cholinesterase. Also, the Pharmaceutical Research and Manufacturers of America (PhRMA) reported that only 3 of 104 possible treatments have been approved in the past 13 years, a 34 to 1 ratio of setbacks to successes.

Joe Harding, professor at the WSU College of Veterinary Medicine, Jay Wright, professor at the WSU College of Arts and Sciences, and other WSU colleagues, reported their findings on October 10, 2012, in the early online section of the Journal of Pharmacology and Experimental Therapeutics. Prof. Harding designed a smaller version of the peptide angiotensin IV. Unlike the original peptide and early candidate molecules based on it, the new analog, Dihexa, was found to be both stable and able to cross the blood-brain barrier. It can also move from the gut into the blood and so could be taken orally in pill form.

The WSU team tested Dihexa on several dozen rats treated with scopolamine. Typically, a rat treated with scopolamine will not learn the location of a submerged platform in a water tank, orienting with cues outside the tank. After receiving Dihexa, all rats learned the task whether receiving the drug orally, by injection, or directly into the brain. Similar results were observed where a smaller group of old rats performed like young rats after treatment; however, while these results were statistically valid, studies with larger test groups will be needed to check the finding.

The "gold standard” compound for creating neuronal connections is brain-derived neurotrophic factor (BDNF). In bench assays using living nerve cells to monitor new neuronal connections, Dihexa was seven orders of magnitude more powerful than BDNF, which itself has yet to be effectively developed for therapeutic use. "We quickly found out that this molecule was [very highly] active,” said Prof. Harding. These results further suggest that Dihexa or molecules like it may also have applications for other neurodegenerative diseases or brain traumas where neuronal connections are lost. Development of Dihexa for human use will begin after safety testing and US Food and Drug Administration approval is obtained for clinical trials.

Related Links:

Washington State University




Channels

Genomics/Proteomics

view channel
Image: The photo shows a mouse pancreatic islet as seen by light microscopy. Beta cells can be recognized by the green insulin staining. Glucagon is labeled in red and the nuclei in blue (Photo courtesy of Wikimedia Commons).

Regenerative Potential Is a Trait of Mature Tissues, Not an Innate Feature of Newly Born Cells

Diabetes researchers have found that the ability of insulin-producing beta cells to replicate and respond to elevated glucose concentrations is absent in very young animals and does not appear until after weaning.... Read more

Biochemistry

view channel
Image:  Model depiction of a novel cellular mechanism by which regulation of cryptochromes Cry1 and Cry2 enables coordination of a protective transcriptional response to DNA damage caused by genotoxic stress (Photo courtesy of the journal eLife, March 2015, Papp SJ, Huber AL, et al.).

Two Proteins Critical for Circadian Cycles Protect Cells from Mutations

Scientists have discovered that two proteins critical for maintaining healthy day-night cycles also have an unexpected role in DNA repair and protecting cells against genetic mutations that could lead... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.